» Articles » PMID: 31318897

The Community Pharmacy Setting for Diabetes Prevention: Views and Perceptions of Stakeholders

Overview
Journal PLoS One
Date 2019 Jul 19
PMID 31318897
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Diabetes prevention programmes delay or prevent the onset of type 2 diabetes in people with pre-diabetes. To increase accessibility, national guidelines recommend delivering diabetes prevention programmes in primary care settings, including community pharmacy. This study aimed to explore the English community pharmacy setting as an option for delivering diabetes prevention services.

Methods: Two focus groups and nine semi-structured interviews were conducted with stakeholders including, community pharmacists, general practitioners and commissioners. The topic guide was framed using the COM-B theoretical model for behaviour change to elicit practitioners' capability, opportunity and motivation to engage with providing or referring to community pharmacy diabetes prevention services. Data were analysed thematically, and barriers/facilitators mapped to the COM-B framework.

Results: Five themes were identified: 'Pre-diabetes management and associated challenges', 'The community pharmacy setting', 'Awareness of community pharmacy services', 'Relationships and communication' and 'Delivery of community pharmacy services'. Community pharmacy was highlighted as an accessible setting for delivering screening and follow-on lifestyle interventions. Key factors for enhancing the capability of community pharmacy teams to deliver the interventions included training and appropriate use of skill mix. Delivering diabetes prevention services in collaboration with general practices was identified as key to the provision of integrated primary care services. Whilst financial incentives were identified as a motivating factor for delivery, service promotion to patients, public and healthcare professionals was perceived as crucial for enhancing engagement.

Conclusions: This research highlights a role for community pharmacy in diabetes prevention. New service models should seek to integrate community pharmacy services in primary care to facilitate patient engagement and better communication with general practices.

Citing Articles

Healthcare workers' perspectives on barriers and facilitators to referral to type 2 diabetes prevention programmes: a systematic review.

Haseldine C, Pallin J, Kearney P, Mc Hugh S, Riordan F, Cotterill S BMJ Open. 2025; 15(3):e090105.

PMID: 40054870 PMC: 11891527. DOI: 10.1136/bmjopen-2024-090105.


Exploring the relationship between professional roles and behavioural intentions in chronic kidney disease management: a cross-sectional study among primary and specialist health professionals in Shanghai, China.

Wu L, Wang W, Liang Y BMJ Open. 2025; 15(1):e083708.

PMID: 39779260 PMC: 11749849. DOI: 10.1136/bmjopen-2023-083708.


A digital health-supported and community pharmacy-based lifestyle intervention program for adults with pre-diabetes: a study protocol for a cluster randomised controlled trial.

Teoh K, Ng C, Chong C, Cheong W, Ng Y, Bell J BMJ Open. 2024; 14(10):e083921.

PMID: 39448216 PMC: 11579589. DOI: 10.1136/bmjopen-2024-083921.


Actual practices of community pharmacists in the management of diabetes: a comparison of simulated patient-based study with perceived role of involvement.

Sendekie A, Tesfaye A, Tadesse Y, Dagnaw A, Belachew E J Pharm Policy Pract. 2024; 17(1):2326381.

PMID: 38562557 PMC: 10984231. DOI: 10.1080/20523211.2024.2326381.


The use of the Capability-Opportunity- Motivation Behavior (COM-B) model to identify barriers to medication adherence and the application of mobile health technology in adults with coronary heart disease: A qualitative study.

Park L, Ng F, Handley M PEC Innov. 2023; 3:100209.

PMID: 37753273 PMC: 10518702. DOI: 10.1016/j.pecinn.2023.100209.


References
1.
Barron E, Clark R, Hewings R, Smith J, Valabhji J . Progress of the Healthier You: NHS Diabetes Prevention Programme: referrals, uptake and participant characteristics. Diabet Med. 2017; 35(4):513-518. PMC: 5873376. DOI: 10.1111/dme.13562. View

2.
Penn L, Rodrigues A, Haste A, Marques M, Budig K, Sainsbury K . NHS Diabetes Prevention Programme in England: formative evaluation of the programme in early phase implementation. BMJ Open. 2018; 8(2):e019467. PMC: 5855311. DOI: 10.1136/bmjopen-2017-019467. View

3.
Todd A, Copeland A, Husband A, Kasim A, Bambra C . The positive pharmacy care law: an area-level analysis of the relationship between community pharmacy distribution, urbanity and social deprivation in England. BMJ Open. 2014; 4(8):e005764. PMC: 4156797. DOI: 10.1136/bmjopen-2014-005764. View

4.
Forouhi N, Luan J, Hennings S, Wareham N . Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet Med. 2007; 24(2):200-7. DOI: 10.1111/j.1464-5491.2007.02068.x. View

5.
Risoy A, Kjome R, Sandberg S, Solvik U . Risk assessment and HbA1c measurement in Norwegian community pharmacies to identify people with undiagnosed type 2 diabetes - A feasibility study. PLoS One. 2018; 13(2):e0191316. PMC: 5825028. DOI: 10.1371/journal.pone.0191316. View